Galapagos NV (GLPG)
Company Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need.
Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.
The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.
In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis.
The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG.
Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Country | BE |
IPO Date | Feb 27, 2012 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 704 |
CEO | Henry Gosebruch |
Contact Details
Address: Generaal De Wittelaan L11 A3 Mechelen, BE | |
Website | https://www.glpg.com |
Stock Details
Ticker Symbol | GLPG |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001421876 |
CUSIP Number | 36315X101 |
ISIN Number | US36315X1019 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Henry Gosebruch | Chief Executive Officer & Executive Director |
Thad Huston C.M.A. | Executive Vice President, Chief Financial Officer & Chief Operating Officer |
Alice Dietrich | Head of Medical Affairs |
Annelies Missotten | Executive Vice President & Chief Human Resources Officer |
Dr. Pierre J.M.B. Raboisson Ph.D., Pharm.D. | Head of Small Molecules Discovery & Senior Vice President |
Ellen Van Der Aar | Head of Development |
Marieke Vermeersch | Head of Corporate Communication |
Patrik Ringblom | Head of Strategy & US Lead |
Philippe Alen M.B.A., Ph.D., Pharm.D. | Senior Vice President & Head of Business Development |
Valeria Cnossen | Executive Vice President & General Counsel |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 28, 2025 | 6-K | Filing |
May 19, 2025 | SCHEDULE 13D/A | [Amend] Filing |
May 14, 2025 | 6-K | Filing |
May 13, 2025 | 6-K | Filing |
Apr 29, 2025 | 6-K | Filing |
Apr 23, 2025 | 6-K | Filing |
Apr 21, 2025 | 6-K | Filing |
Apr 15, 2025 | 6-K | Filing |
Mar 28, 2025 | 6-K | Filing |
Mar 27, 2025 | 20-F | Filing |